SCHEMBL15701152

SCHEMBL15701152

CC(C)C(C(=O)Nc1nc2ccc(NC(=O)c3cscn3)cc2s1)c1cccc(C#N)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 2/20 0.44
DYRK1A Q13627 1/20 0.44
RAB9A P51151 9/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
POLB P06746 2/20 0.41
HPGD P15428 1/20 0.41
GRM4 Q14833 1/20 0.41
CASP3 P42574 2/20 0.40
SENP8 Q96LD8 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
SENP6 Q9GZR1 2/20 0.40
NPC1 O15118 7/20 0.40
MAPT P10636 3/20 0.40
OPRK1 P41145 2/20 0.40
HTT P42858 2/20 0.40
LCK P06239 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
CSNK1D P48730 1/20 0.39
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15701259 0.94 FFAR2 (0.44) FFAR2DYRK1ARAB9AKDM4EALDH1A1
SCHEMBL15701134 0.91 FFAR2 (0.45) FFAR2DYRK1ARAB9AKDM4EALDH1A1
SCHEMBL15701145 0.89 PSEN1 (0.46) DYRK1ARAB9AKDM4EALDH1A1POLB
SCHEMBL15701086 0.89 FFAR2 (0.54) FFAR2RAB9AKDM4EALDH1A1POLB
SCHEMBL15701027 0.88 FFAR2 (0.52) FFAR2DYRK1ARAB9AKDM4EALDH1A1
SCHEMBL17148442 0.87 DYRK1A (0.45) DYRK1ARAB9AKDM4EALDH1A1POLB
SCHEMBL15701234 0.85 CYP2C9 (0.51) FFAR2DYRK1ARAB9AKDM4EALDH1A1
SCHEMBL15701288 0.84 HSD17B1 (0.48) DYRK1ARAB9AKDM4EALDH1A1POLB
SCHEMBL15701024 0.84 RAB9A (0.42) DYRK1ARAB9AKDM4EALDH1A1POLB
SCHEMBL15701099 0.83 DYRK1A (0.45) DYRK1ARAB9AKDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2914592-B1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INT (DE) 2017-10-11 EP disclosed
US-9334249-B2 Inhibitors of cytomegalovirus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-10 US disclosed
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-08 US disclosed
WO-2014070979-A1 INHIBITORS OF CYTOMEGALOVIRUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284348-A1 INHIBITORS OF CYTOMEGALOVIRUS CDKN1A, CCNA1, IFNAR1 FFAR2 4600/4885DYRK1A 3952/4885RAB9A 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.